SCHEMBL7337258

SCHEMBL7337258

NN=Cc1ccc2cc(C(=O)Nc3ccc([N+](=O)[O-])cc3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.56
KMT2A Q03164 9/20 0.50
MEN1 O00255 8/20 0.50
RAB9A P51151 6/20 0.50
NPC1 O15118 4/20 0.50
POLB P06746 3/20 0.50
MITF O75030 2/20 0.50
MAPT P10636 7/20 0.49
HTT P42858 2/20 0.49
ATM Q13315 1/20 0.48
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
PLAT P00750 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7340329 0.84 PLAU (0.63) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL7336457 0.83 NPC1 (0.53) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL7345240 0.81 PLAU (0.64) KMT2AMEN1RAB9ANPC1PLG
SCHEMBL7343089 0.81 PLAU (0.67) KMT2AMEN1RAB9ANPC1PLG
SCHEMBL7343081 0.81 PLAU (0.67) KMT2AMEN1RAB9ANPC1PLG
SCHEMBL7335937 0.81 DEGS1 (0.57) KMT2AMEN1RAB9ANPC1
SCHEMBL7345579 0.80 PLAU (0.65) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL7337241 0.79 PLAU (0.71) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL7337325 0.79 PLAU (0.58) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL7337311 0.79 PLAU (0.58) KMT2AMEN1RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 IKBKB 456/4885KMT2A 4585/4885MEN1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.